ArticleEuropean journal of medical research2025
Prognostic relevance of prospero homeobox 1 and metastasis tumor antigen 1 in patients with malignant salivary gland tumors: a clinicopathological study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe current study aimed to investigate the prognostic relevance of PROX1, and MTA1 in salivary gland carcinomas.
methodsIn a retrospective study on 45 cases diagnosed with salivary gland carcinoma, PROX1 and MTA1 immunoexpressions were assessed concerning the different clinicopathologic parameters, disease-free (DFS), and overall survivals (OS). Pearson's Chi-square test, One-way ANOVA, and Post Hoc tests were used to estimate the difference between groups. The Kaplan-Meier method was used to record DFS and OS, and the log-rank test was used to analyze the data. With Cox regression, univariate and multivariate survival analyses were run. A P-value of 0.05 or less was regarded as statistically significant.
resultsPositive PROX1 and high MTA1 expressions were significantly associated with large tumor sizes (T3 & T4), presence of nodal and distant metastasis, advanced TNM clinical stage (III + IV), and presence of tumor recurrence (P values were ≤ 0.05). Moreover, positive PROX1, and high MTA1 expressions were significantly associated with poor DFS and OS in the univariate models. Additionally, DFS and OS were significantly reduced in relation to large sized tumors (T3 + T4), positive nodal involvement, positive distant metastasis, advanced TNM clinical stage (III + IV), high-grade carcinomas, presence of LV invasion, and old ages (P values were ≤ 0.05). The multivariate analysis with Cox regression found that distant metastasis was the independent predictor for DFS, but not for OS in SGC patients.
conclusionsPROX1 and MTA1 immunoexpression could be used as predictors of progression and recurrence in SGC patients. PROX1 and MTA1 are potentially prognostic, predictive biomarkers, and promising molecular therapeutic targets in SGC patients. Trial registration Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.